Copd News

A team from various Swiss research centers and hospitals conducted a study of more than 300 patients hospitalized with acute exacerbations of COPD.

"[A]n agreement of confidentiality, or circumstances creating a similar expectation of secrecy, may negate a 'public use' where there is not commercial exploitation" [even] when an unaffiliated third party is responsible for the allegedly public use.

People who are consistently exposed to both wood smoke and tobacco smoke are at a greater risk for developing chronic obstructive pulmonary disease and for experiencing more frequent and severe symptoms of the disease, as well as more severe airflow obstruction, than those who are exposed to only one type of smoke, according to the results of a new ... (more)

Researchers found that over 40 percent of patients being treated for COPD at federally funded clinics did not actually have the disease.

First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix' particle engineering platform Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design , has initiated a Phase 2 clinical study with PSX1002 that will ... (more)

In a survey conducted by Decision Resources, a research and advisory firm located in Burlington, Massachusetts, U.S. and European pulmonologists agree that therapies offering a greater effect on quality of life are among the areas of highest unmet need in the treatment of chronic obstructive pulmonary disease .

ATS 2013, PHILADELPHIA People who are consistently exposed to both wood smoke and tobacco smoke are at a greater risk for developing chronic obstructive pulmonary disease and for experiencing more frequent and severe symptoms of the disease, as well as more severe airflow obstruction, than those who are exposed to only one type of smoke, according ... (more)

WASHINGTON & CHICAGO -- -- The COPD Foundation will host COPD8USA , a multi-disciplinary, Continuing Medical Education conference, June 14-15, 2013, Hilton Chicago, 720 S. Michigan Ave., Chicago, Ill.

The single, easiest way to keep track of all the stocks that matter... Your own personalized stock watchlist! It's a 100% FREE Motley Fool service... There's good news and bad news for Americans.

Pearl Therapeutics Inc. today announced the initiation of PINNACLE, a global Phase 3 program of PT003 , the Company's fixed-dose combination of glycopyrrolate, a long-acting muscarinic antagonist and formoterol fumarate, a long-acting beta-2 agonist , delivered via a pressurized hydrofluoroalkane using the Company's novel co-suspension formulation ... (more)

Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21 percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline for its respiratory drugs.

The U.S. Food and Drug Administration has approved a new drug to treat chronic obstructive pulmonary disease, a condition often associated with smoking that can include emphysema, chronic bronchitis, or both.

Patients with chronic obstructive pulmonary disease who also have allergic disease have higher levels of respiratory symptoms and are at higher risk for COPD exacerbations, according to a new study from researchers at Johns Hopkins University in Baltimore.

Crestwood Medical Center in Huntsville is among hospitals across the U.S. featured in a hospital pricing report released by President Obama on Wednesday.

Every Sunday I make it a point to examine a combination of earnings stories or Food and Drug Administration panel reviews or PDUFA decisions in the upcoming week that you can't afford to miss.

Aclidinium/formoterol demonstrates consistent, statistically significant lung function improvement in the second pivotal efficacy trial.

It is no surprise then, that such high revenue originator drugs are attracting interest from prospective generic competitors.

Positive results have been reported from the AUGMENT/COPD trial, the second 6-month pivotal phase III study of investigational fixed-dose combinations of aclidinium bromide and formoterol fumarate , delivered in the Pressair inhaler.

For many of the 12 million Americans with chronic obstructive pulmonary disease or COPD, breathlessness, coughing and mucus production may not be symptoms of a nagging cold, but serious, daily effects of a progressive, irreversible lung disease that includes the respiratory illnesses chronic bronchitis and emphysema.

Forest Laboratories, Inc. and Almirall, S.A. today announced positive topline results from AUGMENT COPD, the second six-month pivotal phase III clinical trial evaluating the efficacy and safety of investigational fixed dose combinations of aclidinium bromide and formoterol fumarate , delivered in the Pressair inhaler.